Rosoxacin (also known as acrosoxacin, tradename Eradacil) is a quinolone antibiotic indicated for the treatment of urinary tract infections and certain sexually transmitted diseases. Rosoxacin is not available in the United States.
It was developed in 1978 by George Lesher and his colleagues at Sterling Drug (now part of Sanofi-Aventis), as an extension of the work that originally led to nalidixic acid.
It is classified as a first generation quinolone.
Synthesis
The synthesis of rosoxacin begins with a modified Hantzsch pyridine synthesis employing as component parts
ammonium acetate, two equivalents of methyl propiolate, and one of 3-nitrobenzaldehyde. Oxidation of the resulting dihydropyridine (
2) with nitric acid followed by saponification, decarboxylation, and reduction of the nitro group with iron and HCl acid gives aniline
3. This undergoes the classic sequence of Gould-Jacobs reaction with methoxymethylenemalonate ester to form the 4-hydroxyquinoline ring, and then alkylation with
ethyl iodide and saponification of the ester to complete the synthesis of the antibacterial agent rosoxacin (
4).
See also
